Cairo – 28 July 2025 – Zilla Capital, a leading investment bank in the MENA region, is pleased to announce the successful completion of its role as the sole financial advisor to Triquera B.V.“Triquera”, the majority shareholder of Minapharm Pharmaceuticals “Minapharm” a leading biotechnology-based pharmaceutical company in the Middle East and Africa, and the key shareholder of ProBioGen AG “ProBioGen”, a leading German CDMO subsidiary of Minapharm, on its capital increase transaction with Virunga Healix Limited managed by Admaius Capital Partners “Admaius”, a prominent Pan-African private equity firm. This strategic capital increase, through which Admaius acquired a minority stake in Triquera, marks a significant milestone in the company’s journey. Triquera and Admaius are joining forces to boost the availability of cutting-edge biologic treatments by accelerating development, expanding production and improving access in underserved markets across Africa and the Middle East. The investment by Admaius provides Triquera with a strong institutional partner to support Minapharm’s ongoing development of complex bioengineered products and innovative therapies, while accelerating its expansion across key markets. This partnership reflects a mutual commitment to advancing healthcare equity through innovation and aligns with Minapharm and ProBioGen’s strategy to enhancing their research and manufacturing capabilities, and continuing to deliver high-quality offerings globally. In this context, Moustafa El-Shenety, Managing Partner of Zilla Capital and Head of Investment Banking, expressed his pride in Zilla Capital’s role in advising Triquera on this landmark transaction. He emphasized that this partnership will support Minapharm in advancing its regional and global strategic objectives and serve as a catalyst for further innovation and global growth in the biotech sector. El-Shenety also expressed his delight in cooperating with Minapharm’s senior management across Egypt and Germany led by the Chairman and CEO Dr. Wafik El Bardissi and Co-CEO Dr. Shaheer El Bardissi. He also highlighted that the transaction signals a strong rebound in Egypt’s pharmaceutical and biotech industries. Zilla Capital team advising Triquera was led by Moustafa El-Shenety and Khaled Gamal (Managing Partners and Co-Heads of Investment Banking), alongside Zilla Capital investment banking team including Omar Zakaria (Director), Mohamed Rady (Assistant Vice President), and Aly Morsy (Associate). Triquera was advised by Matouk Bassiouny & Hennawy as sole legal counsel. The legal team was led by Omar Bassiouny (Founding Partner), Salma El Refaie (Senior Associate), Mayar Sharafeldin (Associate), and Beshoy Mounir (Junior Associate). Admaius was advised by White & Case as sole legal counsel. About Zilla Capital Zilla Capital is a leading Investment Bank in MENA, leveraging its Executive Partners’ extensive experience and network in the region to help our clients achieve their strategic goals through offering comprehensive and integrated financial solutions that cater to their specialized needs. Zilla Capital is a one-stop-shop offering an array of services including financial advisory, asset management, private equity, and non-banking financing solutions. About Triquera B.V. and Minapharm Triquera B.V. is the holding company of Minapharm Pharmaceuticals and Chemical Industries S.A.E. Minapharm is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa with over 25 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex, genetically engineered proteins, with an impressive immunotherapy pipeline. Together with its wholly-owned Berlin-based subsidiary, ProBioGen AG, a globally renowned CDMO and provider of innovative proprietary technologies in the fields of monoclonal antibodies, protein, viral, and cell therapies to the global biotech industry at large, Minapharm has established an integrated business model making it to date the only gene-to-market biopharmaceutical company in the region. About Admaius Capital Partners Admaius Capital Partners is a Pan-African investment manager with over USD 280 million in assets under management through its Virunga Africa Fund 1. Headquartered in Kigali with offices in Nairobi, Johannesburg, Tunis, and London, Admaius is led by a fully African team with deep experience across the continent, including backgrounds at leading firms such as Carlyle, Actis, and Standard Chartered. Zilla Capital Press Contacts: Name: Mohamed Rady Title: Assistant Vice President Email: [email protected] Name: Yassmin Khafagy Title: Marketing Manager Email: [email protected]